P S McKinnon

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi New antibiotics for infections caused by resistant organisms
    P S McKinnon
    Detroit Receiving Hospital and University Health Center, Anti Infective Research Laboratory, Department of Pharmacy Services, 4201 St Antoine Blvd, Detroit, Michigan 48201
    Support Care Cancer 9:8-10. 2001
  2. ncbi Temporal assessment of Candida risk factors in the surgical intensive care unit
    P S McKinnon
    Detroit Receiving Hospital, Detroit, MI, USA
    Arch Surg 136:1401-8; discussion 1409. 2001
  3. ncbi Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases
    P S McKinnon
    Detroit Receiving Hospital, Anti Infective Research Laboratory and Wayne State University, 4201 St Antoine Boulevard, 1B UHC, Detroit, MI 48201, USA
    Eur J Clin Microbiol Infect Dis 23:271-88. 2004
  4. ncbi Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam
    T K Jellison
    Department of Pharmacy Services, Detroit Receiving Hospital, Wayne State University, Michigan 48201, USA
    Pharmacotherapy 21:142-8. 2001
  5. ncbi Pharmacologic considerations in antimicrobial therapy, with emphasis on pharmacokinetics and pharmacodynamics: reviews for the practicing clinician
    P S McKinnon
    Infectious Diseases Pharmacotherapy, Detroit Receiving Hospital and Infectious Diseases Outcome Research, Anti-Infective Research Laboratory, Wayne State University, Detroit, MI 48201, USA
    Eur J Clin Microbiol Infect Dis 23:231-2. 2004

Detail Information

Publications5

  1. ncbi New antibiotics for infections caused by resistant organisms
    P S McKinnon
    Detroit Receiving Hospital and University Health Center, Anti Infective Research Laboratory, Department of Pharmacy Services, 4201 St Antoine Blvd, Detroit, Michigan 48201
    Support Care Cancer 9:8-10. 2001
    ..Other new classes of agents, including the ketolides, everninomycins, and newer glycopeptides, such as LY-333328, are in the early stages of development...
  2. ncbi Temporal assessment of Candida risk factors in the surgical intensive care unit
    P S McKinnon
    Detroit Receiving Hospital, Detroit, MI, USA
    Arch Surg 136:1401-8; discussion 1409. 2001
    ..Risk factors for Candida infection in surgical intensive care units (SICUs) change over time. Risk factor progression may influence Candida colonization and infection...
  3. ncbi Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases
    P S McKinnon
    Detroit Receiving Hospital, Anti Infective Research Laboratory and Wayne State University, 4201 St Antoine Boulevard, 1B UHC, Detroit, MI 48201, USA
    Eur J Clin Microbiol Infect Dis 23:271-88. 2004
    ..Disease states with special considerations for antimicrobial use are reviewed, as are situations in which pathophysiologic changes may alter the pharmacokinetic handling of antimicrobial agents...
  4. ncbi Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam
    T K Jellison
    Department of Pharmacy Services, Detroit Receiving Hospital, Wayne State University, Michigan 48201, USA
    Pharmacotherapy 21:142-8. 2001
    ..004). CONCLUSION: Ampicillin-sulbactam is at least as effective as imipenem-cilastatin based on clinical response at days 2, 7, and end of treatment and is a cost-effective alternative for treatment of A. baumannii infections...
  5. ncbi Pharmacologic considerations in antimicrobial therapy, with emphasis on pharmacokinetics and pharmacodynamics: reviews for the practicing clinician
    P S McKinnon
    Infectious Diseases Pharmacotherapy, Detroit Receiving Hospital and Infectious Diseases Outcome Research, Anti-Infective Research Laboratory, Wayne State University, Detroit, MI 48201, USA
    Eur J Clin Microbiol Infect Dis 23:231-2. 2004